January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Dr. Maosheng Duan, President of Drug Discovery and CMC Divisions at Medicilon, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
About the speaker
Dr. Maosheng Duan holds a Master’s degree in Organic Chemistry from Nankai University in Tianjin, China, as well as a Ph.D. in Organic Chemistry and a Master’s degree in Biochemistry from The Ohio State University in the USA. With over 25 years of experience in the pharmaceutical and biotech industry, Dr. Duan has worked across international big pharma, CROs, and biotech companies, gaining extensive expertise in R&D, operations, and management. Prior to joining Medicilon, Dr. Duan held key leadership roles at prominent organizations, including GSK, HD Biosciences, YueZhi KangTai Biomedicine, and NanoPeptide Biotechnology.
Dr. Duan has directed and led the entire drug research and development process, from project initiation and PCC nomination to IND enabling, filing, and clinical studies. He possesses not only a broad understanding of the drug R&D process but also deep expertise in medicinal chemistry, CMC, biology, pharmacology, pharmacokinetics, toxicology, and clinical regulations. Additionally, Dr. Duan is highly skilled in interpreting diverse types of data to facilitate efficient decision-making.
As a core leader, Dr. Duan excels in guiding cross-functional and interdisciplinary teams, effectively integrating resources to advance R&D pipelines. He has successfully progressed multiple molecules through various stages, from IND filings to clinical studies and NDAs, in the fields of antiviral, antitumor, metabolic diseases, and immunology, with two FDA-approved drugs. Dr. Duan remains at the forefront of biomedical technologies, offering unique insights into cutting-edge areas such as covalent inhibitors, ADCs, PROTACs, and RNAi. His accomplishments include 34 invention patents and 28 publications in peer-reviewed journals.
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
Contact Us
Register as an attendee for ACCESS ASIA BD Forum @ JPM:
For more information, please contact:
Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 